Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 6Breast Neoplasms 2Small Cell Lung Carcinoma 1Recurrence 1Prostate Cancer Metastatic 1Neoplasm Metastasis 1Metastatic Breast Cancer With Intracranial Metastases 1Lung Neoplasms 1Hormone-Resistant Prostate Cancer 1Diarrhea 1Castrate-resistant Metastatic Prostate Cancer 1Carcinoma, Transitional Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 31Gemcitabine 26Nivolumab 20atezolizumab 16Cisplatin 15avelumab 14Carboplatin 12Docetaxel 10enfortumab vedotin 8Magnetic Resonance Spectroscopy 8durvalumab 7Specimen Handling 7Paclitaxel 7Ipilimumab 6toripalimab 5pemigatinib 5cabozantinib 5vinflunine 4sacituzumab govitecan 4Taxes 4Pemetrexed 4tislelizumab 3cabazitaxel 3Standard of Care 3Mitomycin 3Injections 3Everolimus 3Albumin-Bound Paclitaxel 3sapanisertib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Transitional Cell × XRP6258 × Clear all
NCT01437488 2025-05-04

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

Thomas Jefferson University

Phase 2 Completed
14 enrolled 12 charts
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡